A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 4.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

On Tuesday, March 4, 2025, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented at the TD Cowen 45th Annual Healthcare Conference. The company outlined its strategic direction, highlighting both ...